Wave Life Sciences, Inc.

Wave Life Sciences is a clinical-stage biotechnology company developing ribonucleic acid (RNA) medicines to treat rare and prevalent human disorders. Utilizing its proprietary PRISM platform, the company designs stereopure oligonucleotides across modalities including RNA interference, RNA editing, antisense silencing, and splicing. Its therapeutic pipeline focuses on clinical candidates for obesity, alpha-1 antitrypsin deficiency, and PNPLA3-related liver disease, alongside clinical programs targeting Duchenne muscular dystrophy and Huntington’s disease. Wave collaborates with strategic pharmaceutical partners, including GSK, to advance preclinical discovery programs and develop therapeutics addressing both hepatic and extra-hepatic targets.

The company operates an internal manufacturing facility in Lexington, Massachusetts, capable of producing stereopure oligonucleotides from discovery scale to potential commercial volumes. It maintains research and clinical operations primarily across the United States and Europe, conducting multinational clinical trials across various site networks. Waves conducts its corporate, development, and manufacturing activities out of its primary facilities in Massachusetts.

Summary of the business section of Wave Life Sciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 317 employees, all of whom were full-time employees.”